Upload Avatar (500 x 500)
Xingbing Wang
Mayo Clinic College of Medicine
University of Science and Technology of China
Anhui
Language: Chinese, English
Immunotherapy
Hematological Tumors
Clinical Research
Translational Research
Chemotherapy
Molecular Therapy
Targeted Therapy
Cell Therapy
Oncology
Hematology
Areas of Focus
- Basic and clinical translational research on immunotherapy for hematological tumors
- Research on chemotherapy and molecular targeted therapy for hematological tumors
Work Experience
- 2005-07 to Present: Chief Physician, Deputy Director, Department of Hematology, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
- 2012-11 to 2012-12: Visiting Scholar, Oklahoma Medical Research Foundation, USA
- 2013-01 to 2013-09: Visiting Postdoctoral Fellow, Baylor Medical College, USA
Academic Background & Achievements
- 2002-09 to 2005-06: PhD in Internal Medicine, Huazhong University of Science and Technology, Tongji Medical College
- Anhui Provincial Academic and Technical Leader
- Young Leading Talent in Anhui Health System
Publications
- Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies., Xu QW, Xu H, Xue L, Wang L, Zhang XH, Song KD, Yao W, Wan X, Tong J, Liu HL, Liu X, Zhu XY, Sun ZM, Wang XB, 2022
- Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells., Xu Q, Xue L, An F, Xu H, Wang L, Geng L, Zhang X, Song K, Yao W, Wan X, Tong J, Liu H, Liu X, Zhu X, Zhai Z, Sun Z, Wang X, 2022
- Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy., Xue L, Yi Y, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang J, Chen Y, Tao G, Hu B, Wang X, 2021
- CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation., Xu QW, Xu H, Xue L, Wang M, Pan GW, Zhang XH, Song KD, Yao W, Wan X, Tong J, Liu HL, Xu HY, Liu X, Zhu XY, Sun ZM, Yang L, Wang XB, 2022
- CD19 CAR-T细胞治疗复发难治Ph+急性B淋巴细胞白血病14例疗效及安全性., 何彩霞，薛磊，强萍，徐慧，张旭晗，刘欣，朱薇波，蔡晓燕，刘会兰，孙自敏，王兴兵, 2020
- CAR-T细胞治疗混合表型急性白血病一例., 何彩霞，薛磊，翁良银，许倩文，朱薇波，刘欣，王兴兵, 2020
- T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia., Xue L, Hu Y, Wang J, Liu X, Wang X, 2019
- Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma., Sujun Li, Lei Xue, Min Wang, Ping Qiang, Hui Xu, Xuhan Zhang, Wenyao Kang, Fengtao You, Hanying Xu, Yu Wang, Xin Liu, Lin Yang, Xingbing Wang, 2019
- Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy., Xu Q, Shi Y, Xue L, An F, Xu H, Liu X, Zhu X, Sun Z, Zhai Z, Wang X, 2023
- Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies., Wang Y, Sun R, Ge W, Xue L, Xu Q, Xu H, Li S, Wu M, Guo T, Wang X, 2023
Awards
- Anhui Science and Technology Progress Award (2021): Second Prize
- 15th Anhui Youth Science and Technology Award (2013): Personal Award
- Anhui Science and Technology Progress Award (2015): Second Prize
- Anhui Science and Technology Progress Award (2011): Second Prize
